Literature DB >> 4312660

Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.

G Mathé, P Pouillart, F Lapeyraque.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4312660      PMCID： PMC2008494          DOI： 10.1038/bjc.1969.101

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  10 in total

1.  ANTIBODY-INDUCED DEPRESSION OF THE IMMUNE RESPONSE: A STUDY OF THE MECHANISM IN VARIOUS IMMUNOLOGICAL SYSTEMS.

Authors:  G MOLLER
Journal:  Transplantation       Date:  1964-05       Impact factor: 4.939

2.  STUDIES ON IMMUNITY TO LEUKEMIA L1210 IN MICE.

Authors:  J P GLYNN; S R HUMPHREYS; G TRIVERS; A R BIANCO; A GOLDIN
Journal:  Cancer Res       Date:  1963-08       Impact factor: 12.701

3.  [Effect of inoculation with Calmette-Guerin bacillus on the development of Ehrlich ascites tumor in the mouse].

Authors:  G BIOZZI; C STIFFEL; B N HALPERN; D MOUTON
Journal:  C R Seances Soc Biol Fil       Date:  1959

4.  Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse.

Authors:  L J OLD; D A CLARKE; B BENACERRAF
Journal:  Nature       Date:  1959-07-25       Impact factor: 49.962

5.  [Active immunotherapy of L 1210 leukemia given after the graft of the tumor].

Authors:  G Mathé
Journal:  Rev Fr Etud Clin Biol       Date:  1968-11

6.  [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].

Authors:  G Mathé; L Schwarzenberg; M Hayat; M Schneider
Journal:  Rev Fr Etud Clin Biol       Date:  1968-12

7.  [Demonstration of the efficacy of active immunotherapy in human acute lymphoblastic leukemia].

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F de Vassal
Journal:  Rev Fr Etud Clin Biol       Date:  1968-05

8.  [Non specific active immunotherapy by B.C.G. in virus induced leukemia in E male G2 mice in isogenic receiptients].

Authors:  J L Amiel
Journal:  Rev Fr Etud Clin Biol       Date:  1967-11

9.  Inhibition of tumour growth by administration of killed corynebacterium parvum.

Authors:  B N Halpern; G Biozzi; C Stiffel; D Mouton
Journal:  Nature       Date:  1966-11-19       Impact factor: 49.962

10.  Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts.

Authors:  M F Woodruff; J L Boak
Journal:  Br J Cancer       Date:  1966-06       Impact factor: 7.640
  10 in total
  45 in total

1.  Enhancement of avian sarcoma virus-induced tumor growth after pretreatment with BCG.

Authors:  M A Wainberg; E Israel
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

2.  New experimental and clinical data on leukaemia immunotherapy.

Authors:  G Mathé; L Schwarzenberg; J L Amiel; P Pouillart; M Hayat; F de Vassal; C Rosenfeld; C Jasmin
Journal:  Proc R Soc Med       Date:  1975-04

3.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

Review 4.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

5.  Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report.

Authors:  W Bakker; J M Nijhuis-Heddes; E A van der Velde
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells.

Authors:  R L Simmons; A Rios
Journal:  Ann Surg       Date:  1972-08       Impact factor: 12.969

7.  Current status of immunotherapy.

Authors:  A Coates
Journal:  Drugs       Date:  1974       Impact factor: 9.546

8.  Enhancement of resistance and suppression of immunization against experimental Trypanosoma cruzi infection by Corynebacterium parvum.

Authors:  F Kierszenbaum
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

Review 9.  Cancer immunotherapy.

Authors:  S P Richman; J U Gutterman; E M Hersh
Journal:  Can Med Assoc J       Date:  1979-02-03       Impact factor: 8.262

10.  Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy.

Authors:  R L Powles; T A Lister; R T Oliver; J Russell; C Smith; H E Kay; T J McElwain; G H Fairley
Journal:  Br Med J       Date:  1974-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.